Literature DB >> 14657775

The comparative effects of sevoflurane and methohexital for electroconvulsive therapy.

Chadi A Calarge1, Raymond R Crowe, Samir D Gergis, Stephan Arndt, Robert P From.   

Abstract

The standard anesthetic agent for electroconvulsive therapy (ECT) has been methohexital. We compared sevoflurane, a short-acting halogenated anesthetic, to methohexital for induction in ECT. Twelve subjects received sevoflurane or methohexital on alternating treatment days. Seizure duration, time to administering ECT, emergence and recovery, as well as several hemodynamic measures were recorded. A total of 69 treatments were analyzed. When sevoflurane was used, seizure durations recorded by observation and by EEG, were shorter by 10 and 23 seconds, respectively. With sevoflurane, seizure duration remained, however, within a clinically acceptable range. Methohexital allowed faster administration of ECT and discharge from the recovery room (3.8 vs. 6.2 minutes and 40.8 vs. 47.0 minutes, respectively). No difference in the post-ECT hemodynamic changes was found between the two treatments. We conclude that, when indicated, sevoflurane could provide a suitable alternative treatment option to methohexital, but some limitations, including shortened seizure duration and potential side effects, should be kept in mind.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657775     DOI: 10.1097/00124509-200312000-00008

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  2 in total

1.  Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy.

Authors:  Feray Erdil; Zekine Begeç; Gülay Erdoğan Kayhan; Saim Yoloğlu; Mehmet Özcan Ersoy; Mahmut Durmuş
Journal:  J Anesth       Date:  2014-08-02       Impact factor: 2.078

2.  Impact of Sevoflurane and Thiopental Used Over the Course of Electroconvulsive Therapy: Propensity Score Matching Analysis.

Authors:  Taisuke Yatomi; Takahito Uchida; Akihiro Takamiya; Masataka Wada; Shun Kudo; Kazuki Nakajima; Hana Nishida; Bun Yamagata; Masaru Mimura; Jinichi Hirano
Journal:  Front Hum Neurosci       Date:  2022-07-08       Impact factor: 3.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.